Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection has driven strong sales, contributing to the company’s overall revenue ...

On the policy front, the U.S. Senate passed the Biosecure Act, legislation designed to limit federal reliance on certain foreign biotechnology companies viewed as national security risks. The measure ...

Eli Lilly and Co. announced Thursday, Dec. 18 that its experimental daily GLP-1 pill, orforglipron, successfully helped ...